FY2023 Earnings Estimate for Provention Bio, Inc. (NASDAQ:PRVB) Issued By Cantor Fitzgerald

Provention Bio, Inc. (NASDAQ:PRVBGet Rating) – Equities researchers at Cantor Fitzgerald increased their FY2023 earnings per share estimates for shares of Provention Bio in a research report issued on Monday, November 21st. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will post earnings per share of ($1.83) for the year, up from their prior estimate of ($1.95). The consensus estimate for Provention Bio’s current full-year earnings is ($1.62) per share.

PRVB has been the subject of a number of other research reports. SVB Leerink raised their price objective on Provention Bio from $16.00 to $19.00 and gave the stock an “outperform” rating in a research report on Monday. Oppenheimer raised their target price on Provention Bio from $14.00 to $18.00 and gave the stock an “outperform” rating in a research report on Friday, November 18th. Jefferies Financial Group raised their target price on Provention Bio from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, November 18th. Finally, Chardan Capital raised their target price on Provention Bio from $24.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, November 18th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $21.40.

Provention Bio Price Performance

Shares of PRVB stock opened at $9.41 on Wednesday. The stock has a 50 day moving average of $6.57 and a two-hundred day moving average of $5.10. The company has a current ratio of 7.58, a quick ratio of 7.58 and a debt-to-equity ratio of 0.16. Provention Bio has a 12 month low of $3.18 and a 12 month high of $9.65. The company has a market capitalization of $820.47 million, a P/E ratio of -6.03 and a beta of 2.36.

Institutional Investors Weigh In On Provention Bio

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bioimpact Capital LLC acquired a new stake in Provention Bio during the 2nd quarter valued at $2,370,000. Nisa Investment Advisors LLC acquired a new stake in Provention Bio during the 1st quarter valued at $332,000. Rice Hall James & Associates LLC increased its holdings in Provention Bio by 2.6% during the 2nd quarter. Rice Hall James & Associates LLC now owns 225,785 shares of the company’s stock valued at $903,000 after purchasing an additional 5,720 shares in the last quarter. Amalgamated Bank acquired a new stake in Provention Bio during the 1st quarter valued at $49,000. Finally, Sigma Planning Corp increased its holdings in Provention Bio by 22.3% during the 2nd quarter. Sigma Planning Corp now owns 153,690 shares of the company’s stock valued at $615,000 after purchasing an additional 28,070 shares in the last quarter. 37.39% of the stock is owned by institutional investors and hedge funds.

About Provention Bio

(Get Rating)

Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease.

Featured Articles

Earnings History and Estimates for Provention Bio (NASDAQ:PRVB)

Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.